A Phase 4 interventional study of Formoterol 12 mcg and Fluticasone propionate 100 mcg in Persistent Asthma, sponsored by Novartis Pharmaceuticals. Terminated at 27 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.
Among the 86 studies testing formoterol in Asthma, this one is the 15th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 in phase 4, and was the 62nd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 827 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 85 interventional studies. Of the 76 that completed or were terminated, 29 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 86 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
105 studies in Asthma by Novartis: 3 open now, 5 under way, 2 of them phase 3. Of 93 finished, 61 (66%) have results posted.
Among the 105 studies in Asthma by Novartis, this one is the 10th largest by enrollment of the 97 interventional ones that give a count, is one of 5 that started in 2013, is one of 13 in phase 4, and was the 64th registered.
Novartis’s Asthma studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 86 studies testing formoterol in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 105 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone propionate alone.
This was a 26 week, double blind, randomized, active-controlled safety study of Foradil in free combination with inhaled corticosteroid versus an inhaled corticosteroid alone in adults and adolescent patients with persistent asthma. The primary objective of the study was to demonstrate that the addition of formoterol fumarate to fluticasone propionate is non-inferior to fluticasone propionate alone in terms of the risk of composite serious asthma related events (asthma-related hospitalization, asthma-related intubation, and asthma-related death). The individual components of the composite primary endpoint (i.e., asthma-related hospitalization, asthma-related intubation and asthma-related death) will be assessed as a secondary safety endpoints.
The efficacy assessment is the secondary objective.
Key Inclusion Criteria:
Recent asthma exacerbation between 30 days and 12 months prior to randomization that either:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
Drug: Formoterol 12 mcg · Drug: Fluticasone propionate 100 mcg · Drug: Fluticasone propionate 250 mcg · Drug: Fluticasone propionate 500 mcg
fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
Drug: Fluticasone propionate 100 mcg · Drug: Fluticasone propionate 250 mcg · Drug: Fluticasone propionate 500 mcg · Drug: Placebo
Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
Also known as: FOR258
Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
Placebo to match formoterol one inhalation twice daily via dry powder inhaler
Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks
The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 \* n patients with any events / total N patients in treatment group.
Time frame: 26 weeks
Number of Asthma Exacerbations at 26 Weeks
Number of asthma exacerbations events
Time frame: 26 weeks
Percentage of Days of School/Work Missed at 26 Weeks
The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.
Time frame: 26 weeks
Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks
The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.
Time frame: 26 weeks
Percentage of Days With Nighttime Awakenings at 26 Weeks
Percentage of days with nighttime awakenings during the treatment period (26 weeks)
Time frame: 26 weeks
Percentage of Days With no Rescue Medication Use at 26 Weeks
Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.
Time frame: 26 weeks
Percentage of Days With no Symptoms at 26 Weeks
Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.
Time frame: 26 weeks
Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26
Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.
Time frame: baseline and 26 weeks
Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)
Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (\< 24 hours); Hospital admission or Emergency department visit (\> 24 hours).
Time frame: Week 4, Week 12, and Week 26
Following the decision to stop further enrollment into the study, 1121 patients had been screened, of whom 825 were randomized. Of the 820 patients randomized and treated and part of Intent To Treat (ITT analysis) 5 patients were randomized but were excluded from the ITT analyses as they did not take study medication.
| Milestone | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Started | 411 | 409 |
| Completed | 326 | 332 |
| Not completed | 85 | 77 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Unsatisfactory therapeutic effect | 4 | 2 |
| Withdrew: Withdrawal by subject | 48 | 44 |
| Withdrew: Lost to follow-up | 13 | 13 |
| Withdrew: Administrative problems | 8 | 8 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Protocol deviation | 3 | 6 |
| Withdrew: Missing | 1 | 1 |
The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 \* n patients with any events / total N patients in treatment group.
| number of occurences | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Composite event | 3 | 3 |
| Asthma-related death | 0 | 0 |
| Asthma-related intubation | 0 | 0 |
| Asthma-related hospitalization | 3 | 3 |
Number of asthma exacerbations events
| events | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Number of Asthma Exacerbations at 26 Weeks | 1.3 ± 0.62 | 1.2 ± 0.51 |
The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.
| percentage of days | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Percentage of Days of School/Work Missed at 26 Weeks | 0.97 ± 4.558 | 0.56 ± 1.641 |
The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.
| percentage of days | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks | 4.73 ± 12.774 | 4.75 ± 12.705 |
Percentage of days with nighttime awakenings during the treatment period (26 weeks)
| percentage of days | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Percentage of Days With Nighttime Awakenings at 26 Weeks | 4.55 ± 9.577 | 4.20 ± 8.956 |
Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.
| percentage of days | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Percentage of Days With no Rescue Medication Use at 26 Weeks | 76.97 ± 27.255 | 73.29 ± 30.640 |
Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.
| percentage of days | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Percentage of Days With no Symptoms at 26 Weeks | 79.47 ± 25.501 | 77.64 ± 28.394 |
Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.
| total score on a scale | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26 | -0.65 ± 1.224 | -0.59 ± 1.094 |
Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (\< 24 hours); Hospital admission or Emergency department visit (\> 24 hours).
| unplanned visits | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| Telephone contact with study MD: V3 | 19 | 18 |
| Telephone contact with other MD or HCP: V3 | 5 | 9 |
| unplanned visit to study MD;include home:V3 | 7 | 13 |
| unplanned visit to other MD or HCP incl.home:V3 | 5 | 9 |
| Emergency or hospital visit (< 24 hours):V3 | 3 | 4 |
| Hospital admission or Emergency visit (>24hrs):V3 | 1 | 1 |
| Telephone contact with study MD: V4 | 25 | 17 |
| Telephone contact with other MD or HCP: V4 | 5 | 7 |
| unplanned visit to study MD;include home:V4 | 10 | 15 |
| unplanned visit to other MD or HCP incl.home:V4 | 15 | 16 |
| Emergency or hospital visit (< 24 hours):V4 | 3 | 4 |
| Hospital admission or Emergency visit (>24hrs):V4 | 0 | 2 |
| Telephone contact with study MD: V5 | 14 | 9 |
| Telephone contact with other MD or HCP: V5 | 8 | 2 |
| unplanned visit to study MD;include home:V5 | 6 | 9 |
| unplanned visit to other MD or HCP incl.home:V5 | 10 | 7 |
| Emergency or hospital visit (< 24 hours):V5 | 4 | 6 |
| Hospital admission or Emergency visit (>24hrs):V5 | 2 | 0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FOM 12 mcg + FP | — | 10/411 (2.4%) | 5/411 (1.2%) |
| Fluticasone Propionate (FP) | — | 9/409 (2.2%) | 9/409 (2.2%) |
| Event | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/411 | 2/409 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/411 | 0/409 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/411 | 1/409 |
| CellulitisInfections and infestations | 0/411 | 1/409 |
| PneumoniaInfections and infestations | 1/411 | 1/409 |
| TracheobronchitisInfections and infestations | 0/411 | 1/409 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/411 | 1/409 |
| OverdoseInjury, poisoning and procedural complications | 0/411 | 1/409 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/411 | 1/409 |
| Cerebrovascular accidentNervous system disorders | 0/411 | 1/409 |
| Event | FOM 12 mcg + FP | Fluticasone Propionate (FP) |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 5/411 | 9/409 |
| Age, Continuous(years) | FOM 12 mcg + FP | Fluticasone Propionate (FP) | Total |
|---|---|---|---|
| Mean | 44.7 ± 16.67 | 45.6 ± 17.02 | 45.2 ± 16.84 |
| Sex: Female, Male(Participants) | FOM 12 mcg + FP | Fluticasone Propionate (FP) | Total |
|---|---|---|---|
| Female | 284 | 272 | 556 |
| Male | 127 | 137 | 264 |
The record gives a start of May 2013, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol